Form 4: Acrivon Therapeutics CEO Peter Blume-Jensen Reports Tax-Related Stock Disposal
SEC Form 4 Filing
Peter Blume-Jensen, CEO of Acrivon Therapeutics, reports the disposal of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On August 14, 2024, Peter Blume-Jensen, the President and CEO of Acrivon Therapeutics, Inc. [ACRV], reported a transaction involving common stock.
- The transaction involved the disposal of 59,765 shares of common stock at a price of $7.02 per share.
- These shares were withheld by the issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
- Following the transaction, Blume-Jensen directly owns 2,502,129 shares of common stock.
- Additionally, 317,246 shares are held by Kristina Masson, Blume-Jensen's spouse, for which he disclaims beneficial ownership except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document reports a routine transaction related to tax obligations, which is neutral in sentiment.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves a small percentage of the CEO's holdings.
Key Dates
| Date | Description |
|---|---|
| 08/14/2024 | Date of stock disposal transaction |
| 08/16/2024 | Date of signature for the report |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.